
It is indicated for the treatment of adult patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM) classified as New York Heart Association (NYHA) Class Ⅱ-Ⅲ, to improve their functional capacity and symptoms.
FDA,2025.04

Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp: